14.50
-0.18 (-1.23%)
| Penutupan Terdahulu | 14.68 |
| Buka | 15.01 |
| Jumlah Dagangan | 121,374 |
| Purata Dagangan (3B) | 288,160 |
| Modal Pasaran | 377,746,752 |
| Harga / Pendapatan (P/E Ke hadapan) | 41.32 |
| Harga / Jualan (P/S) | 11.51 |
| Harga / Buku (P/B) | 19.04 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 18 Mar 2025 |
| Margin Keuntungan | -9.80% |
| Margin Operasi (TTM) | 8.96% |
| EPS Cair (TTM) | -0.150 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 59.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 122.79% |
| Nisbah Semasa (MRQ) | 2.06 |
| Aliran Tunai Operasi (OCF TTM) | 2.12 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -18.78 M |
| Pulangan Atas Aset (ROA TTM) | -2.53% |
| Pulangan Atas Ekuiti (ROE TTM) | -19.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menurun | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menurun | Bercampur | |
| Stok | Eton Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 3.13 |
|
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 5.57% |
| % Dimiliki oleh Institusi | 48.62% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 33.00 (HC Wainwright & Co., 127.59%) | Beli |
| Median | 28.00 (93.10%) | |
| Rendah | 26.00 (B. Riley Securities, 79.31%) | Beli |
| Purata | 29.00 (100.00%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 16.98 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B. Riley Securities | 16 May 2025 | 26.00 (79.31%) | Beli | 18.93 |
| 19 Mar 2025 | 24.00 (65.52%) | Beli | 14.88 | |
| Craig-Hallum | 14 May 2025 | 28.00 (93.10%) | Beli | 17.12 |
| 19 Mar 2025 | 26.00 (79.31%) | Beli | 14.88 | |
| HC Wainwright & Co. | 19 Mar 2025 | 33.00 (127.59%) | Beli | 14.88 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 14 May 2025 | Pengumuman | Eton Pharmaceuticals to Participate at Upcoming Investor Conferences |
| 13 May 2025 | Pengumuman | Eton Pharmaceuticals Reports First Quarter 2025 Financial Results |
| 01 May 2025 | Pengumuman | Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025 |
| 28 Apr 2025 | Pengumuman | Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) |
| 01 Apr 2025 | Pengumuman | Eton Pharmaceuticals Out-Licenses International Rights to Increlex® |
| 18 Mar 2025 | Pengumuman | Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results |
| 14 Mar 2025 | Pengumuman | Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 |
| 04 Mar 2025 | Pengumuman | Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025 |
| 03 Mar 2025 | Pengumuman | Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |